Abstract
Fourteen patients with previously treated, locally advanced/metastatic transitional cell carcinoma (TCC) of the bladder or ureter received paclitaxel at a dose of 200 mg m-2 administered as a 3-h infusion every 21 days. The activity of paclitaxel in this group of patients was modest. The response rates were one partial response (PR) (7%) and three stable disease (SD). There were two early deaths.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Papamichael, D., Gallagher, C., Oliver, R. et al. Phase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter. Br J Cancer 75, 606–607 (1997). https://doi.org/10.1038/bjc.1997.106
Issue Date:
DOI: https://doi.org/10.1038/bjc.1997.106
This article is cited by
-
Progress in systemic therapy for advanced-stage urothelial carcinoma
Nature Reviews Clinical Oncology (2024)
-
Beyond first-line systemic treatment for metastatic urothelial carcinoma of the bladder
Clinical and Translational Oncology (2019)
-
Atezolizumab in Metastatic Urothelial Carcinoma Outside Clinical Trials: Focus on Efficacy, Safety, and Response to Subsequent Therapies
Targeted Oncology (2018)
-
Improving Systemic Chemotherapy for Bladder Cancer
Current Oncology Reports (2016)
-
Metastatic Bladder Cancer: Second-Line Treatment and Recommendations of the Genitourinary Tumor Division of the Galician Oncologic Society (SOG-GU)
Current Oncology Reports (2016)
